Abstracts tagged "laboratory tests and uric acid"

Abstract Number: 1124 • 2017 ACR/ARHP Annual Meeting
Marked Variability of Circulating Urate Concentrations in Banked Samples Based on Sample Type and Assay
Evan M. Ryan¹, Michael J. Duryee², Susan K. Dover³, Elizabeth Schoenecker³, Risa Urbauer³, Flordeliza Faulkner³, Nicole Norotsky³, Harlan Sayles¹, Brian W Coburn⁴, Samuel Pirruccello¹, Geoffrey M. Thiele¹ and Ted R. Mikuls⁵, ¹University of Nebraska Medical Center, Omaha, NE, ²Internal Medicine Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ³U.S. Department of Veterans Affairs, Omaha, NE, ⁴Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ⁵Internal Medicine, Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Circulating urate is an important biomarker, not only in the detection and management of gout, but also in assessing the risk of related comorbidity.…
Abstract Number: 2241 • 2015 ACR/ARHP Annual Meeting
Treating to Target in Gout: The Epidemiology of Serum Urate Measurement Among Patients with Incident Gout in Usual Care Settings in the United States
Marsha Raebel¹, Liza Reifler¹, David Tabano¹, Kristin Goddard¹, Andrew Sterrett¹, T Craig Cheetham², Leslie Harrold³, Daniel Sapp⁴, Mark Schmidt⁴, Javier Nuevo⁵, Robert Morlock⁶ and Gregory Nichols⁴, ¹Institute for Health Research, Kaiser Permanente Colorado, Denver, CO, ²Kaiser Permanente Southern California, Pasadena, CA, ³Dept of Medicine, UMass Medical School, Worcester, MA, ⁴Center for Health Research, Kaiser Permanente Northwest, Portland, OR, ⁵AstraZeneca, Madrid, Spain, Madrid, Spain, ⁶Ardea Bioscience, San Diego, CA
Background/Purpose: American College of Rheumatology (ACR) guidelines recommend lowering serum urate (sUA) to a target value in patients with gout to prevent crystal deposition/promote crystal…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].